Cargando…

A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial

Mobile applications are increasingly used in healthcare. We have developed a smartphone healthcare application, CALO mama Plus, that can register daily diet, exercise, mood, and sleep quality, calculate dietary intake, and provide advice using artificial intelligence technology. This 3-month randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakata, Yoshio, Sasai, Hiroyuki, Gosho, Masahiko, Kobayashi, Hiroyuki, Shi, Yutong, Ohigashi, Tomohiro, Mizuno, Shinichiro, Murayama, Chiaki, Kobayashi, Satomi, Sasaki, Yuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655114/
https://www.ncbi.nlm.nih.gov/pubmed/36364870
http://dx.doi.org/10.3390/nu14214608
_version_ 1784829106305630208
author Nakata, Yoshio
Sasai, Hiroyuki
Gosho, Masahiko
Kobayashi, Hiroyuki
Shi, Yutong
Ohigashi, Tomohiro
Mizuno, Shinichiro
Murayama, Chiaki
Kobayashi, Satomi
Sasaki, Yuki
author_facet Nakata, Yoshio
Sasai, Hiroyuki
Gosho, Masahiko
Kobayashi, Hiroyuki
Shi, Yutong
Ohigashi, Tomohiro
Mizuno, Shinichiro
Murayama, Chiaki
Kobayashi, Satomi
Sasaki, Yuki
author_sort Nakata, Yoshio
collection PubMed
description Mobile applications are increasingly used in healthcare. We have developed a smartphone healthcare application, CALO mama Plus, that can register daily diet, exercise, mood, and sleep quality, calculate dietary intake, and provide advice using artificial intelligence technology. This 3-month randomized controlled trial tested the hypothesis that CALO mama Plus could promote body weight reduction in Japanese adults with overweight or obesity. We recruited office workers as participants. The key eligibility criteria were an age of 20–65 years and a body mass index of 23–40 kg/m(2). The primary outcome was body weight change over 3 months. We enrolled 141 participants and randomly assigned them to the intervention (n = 72) and control (n = 69) groups. The intervention group used CALO mama Plus, and the control group did not receive any intervention. The change in body weight was −2.4 ± 4.0 kg and −0.7 ± 3.3 kg in the intervention and control groups, respectively. An analysis of covariance adjusted for related variables showed a significant between-group difference in body weight change (−1.60 kg; 95% confidence interval −2.83 to −0.38; p = 0.011). The present study suggests that CALO mama Plus effectively promotes weight loss.
format Online
Article
Text
id pubmed-9655114
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96551142022-11-15 A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial Nakata, Yoshio Sasai, Hiroyuki Gosho, Masahiko Kobayashi, Hiroyuki Shi, Yutong Ohigashi, Tomohiro Mizuno, Shinichiro Murayama, Chiaki Kobayashi, Satomi Sasaki, Yuki Nutrients Article Mobile applications are increasingly used in healthcare. We have developed a smartphone healthcare application, CALO mama Plus, that can register daily diet, exercise, mood, and sleep quality, calculate dietary intake, and provide advice using artificial intelligence technology. This 3-month randomized controlled trial tested the hypothesis that CALO mama Plus could promote body weight reduction in Japanese adults with overweight or obesity. We recruited office workers as participants. The key eligibility criteria were an age of 20–65 years and a body mass index of 23–40 kg/m(2). The primary outcome was body weight change over 3 months. We enrolled 141 participants and randomly assigned them to the intervention (n = 72) and control (n = 69) groups. The intervention group used CALO mama Plus, and the control group did not receive any intervention. The change in body weight was −2.4 ± 4.0 kg and −0.7 ± 3.3 kg in the intervention and control groups, respectively. An analysis of covariance adjusted for related variables showed a significant between-group difference in body weight change (−1.60 kg; 95% confidence interval −2.83 to −0.38; p = 0.011). The present study suggests that CALO mama Plus effectively promotes weight loss. MDPI 2022-11-02 /pmc/articles/PMC9655114/ /pubmed/36364870 http://dx.doi.org/10.3390/nu14214608 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nakata, Yoshio
Sasai, Hiroyuki
Gosho, Masahiko
Kobayashi, Hiroyuki
Shi, Yutong
Ohigashi, Tomohiro
Mizuno, Shinichiro
Murayama, Chiaki
Kobayashi, Satomi
Sasaki, Yuki
A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial
title A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial
title_full A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial
title_fullStr A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial
title_full_unstemmed A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial
title_short A Smartphone Healthcare Application, CALO mama Plus, to Promote Weight Loss: A Randomized Controlled Trial
title_sort smartphone healthcare application, calo mama plus, to promote weight loss: a randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655114/
https://www.ncbi.nlm.nih.gov/pubmed/36364870
http://dx.doi.org/10.3390/nu14214608
work_keys_str_mv AT nakatayoshio asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT sasaihiroyuki asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT goshomasahiko asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT kobayashihiroyuki asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT shiyutong asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT ohigashitomohiro asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT mizunoshinichiro asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT murayamachiaki asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT kobayashisatomi asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT sasakiyuki asmartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT nakatayoshio smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT sasaihiroyuki smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT goshomasahiko smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT kobayashihiroyuki smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT shiyutong smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT ohigashitomohiro smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT mizunoshinichiro smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT murayamachiaki smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT kobayashisatomi smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial
AT sasakiyuki smartphonehealthcareapplicationcalomamaplustopromoteweightlossarandomizedcontrolledtrial